ID   CHIP_RAT                Reviewed;         304 AA.
AC   A6HD62; D4A4T0;
DT   27-MAR-2024, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2023, sequence version 1.
DT   24-JUL-2024, entry version 7.
DE   RecName: Full=E3 ubiquitin-protein ligase CHIP {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000250|UniProtKB:Q9UNE7};
DE   AltName: Full=Carboxy terminus of Hsp70-interacting protein {ECO:0000250|UniProtKB:Q9UNE7};
DE   AltName: Full=RING-type E3 ubiquitin transferase CHIP {ECO:0000305};
DE   AltName: Full=STIP1 homology and U box-containing protein 1 {ECO:0000312|RGD:1306167};
GN   Name=Stub1 {ECO:0000312|RGD:1306167};
GN   Synonyms=Chip {ECO:0000303|PubMed:20724525};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116 {ECO:0000312|Proteomes:UP000002494};
RN   [1] {ECO:0000312|Proteomes:UP000002494}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000312|Proteomes:UP000002494};
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [2] {ECO:0000312|EMBL:EDM03968.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000312|EMBL:EDM03968.1};
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION BY BLOOD
RP   FLOW CESSATION INJURY.
RX   PubMed=19483080; DOI=10.1074/jbc.m109.017046;
RA   Li F., Xie P., Fan Y., Zhang H., Zheng L., Gu D., Patterson C., Li H.;
RT   "C terminus of Hsc70-interacting protein promotes smooth muscle cell
RT   proliferation and survival through ubiquitin-mediated degradation of
RT   FoxO1.";
RL   J. Biol. Chem. 284:20090-20098(2009).
RN   [4] {ECO:0000305}
RP   FUNCTION, INTERACTION WITH MYOCD AND HSPA1A, AND SUBCELLULAR LOCATION.
RX   PubMed=19237536; DOI=10.1128/mcb.01737-08;
RA   Xie P., Fan Y., Zhang H., Zhang Y., She M., Gu D., Patterson C., Li H.;
RT   "CHIP represses myocardin-induced smooth muscle cell differentiation via
RT   ubiquitin-mediated proteasomal degradation.";
RL   Mol. Cell. Biol. 29:2398-2408(2009).
RN   [5] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=20724525; DOI=10.1096/fj.10-162636;
RA   Woo C.H., Le N.T., Shishido T., Chang E., Lee H., Heo K.S., Mickelsen D.M.,
RA   Lu Y., McClain C., Spangenberg T., Yan C., Molina C.A., Yang J.,
RA   Patterson C., Abe J.;
RT   "Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin
RT   ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-
RT   mediated degradation of inducible cAMP early repressor.";
RL   FASEB J. 24:4917-4928(2010).
RN   [6] {ECO:0000305}
RP   FUNCTION, INTERACTION WITH ESR1 AND ESR2, AND TISSUE SPECIFICITY.
RX   PubMed=21808025; DOI=10.1073/pnas.1104391108;
RA   Zhang Q.G., Han D., Wang R.M., Dong Y., Yang F., Vadlamudi R.K.,
RA   Brann D.W.;
RT   "C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of
RT   hippocampal estrogen receptor-alpha and the critical period hypothesis of
RT   estrogen neuroprotection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:E617-E624(2011).
RN   [7] {ECO:0000305}
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH UBXN2A; VCP AND CHRNA3.
RX   PubMed=26265139; DOI=10.1016/j.bcp.2015.08.084;
RA   Teng Y., Rezvani K., De Biasi M.;
RT   "UBXN2A regulates nicotinic receptor degradation by modulating the E3
RT   ligase activity of CHIP.";
RL   Biochem. Pharmacol. 97:518-530(2015).
RN   [8] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND INDUCTION BY
RP   OXYGEN AND GLUCOSE DEPRIVATION.
RX   PubMed=29934347; DOI=10.1523/jneurosci.0699-18.2018;
RA   Lizama B.N., Palubinsky A.M., Raveendran V.A., Moore A.M., Federspiel J.D.,
RA   Codreanu S.G., Liebler D.C., McLaughlin B.;
RT   "Neuronal Preconditioning Requires the Mitophagic Activity of C-terminus of
RT   HSC70-Interacting Protein.";
RL   J. Neurosci. 38:6825-6840(2018).
RN   [9]
RP   FUNCTION, INTERACTION WITH NFATC3, AND SUBCELLULAR LOCATION.
RX   PubMed=30980393; DOI=10.1002/jcp.28614;
RA   Chao C.N., Lai C.H., Badrealam K.F., Lo J.F., Shen C.Y., Chen C.H.,
RA   Chen R.J., Viswanadha V.P., Kuo W.W., Huang C.Y.;
RT   "CHIP attenuates lipopolysaccharide-induced cardiac hypertrophy and
RT   apoptosis by promoting NFATc3 proteasomal degradation.";
RL   J. Cell. Physiol. 234:20128-20138(2019).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which targets misfolded chaperone
CC       substrates towards proteasomal degradation (PubMed:26265139). Plays a
CC       role in the maintenance of mitochondrial morphology and promotes
CC       mitophagic removal of dysfunctional mitochondria; thereby acts as a
CC       protector against apoptosis in response to cellular stress
CC       (PubMed:29934347). Negatively regulates vascular smooth muscle
CC       contraction, via degradation of the transcriptional activator MYOCD and
CC       subsequent loss of transcription of genes involved in vascular smooth
CC       muscle contraction (PubMed:19237536). Promotes survival and
CC       proliferation of cardiac smooth muscle cells via ubiquitination and
CC       degradation of FOXO1, resulting in subsequent repression of FOXO1-
CC       mediated transcription of pro-apoptotic genes (PubMed:19483080).
CC       Ubiquitinates ICER-type isoforms of CREM and targets them for
CC       proteasomal degradation, thereby acts as a positive effector of
CC       MAPK/ERK-mediated inhibition of apoptosis in cardiomyocytes
CC       (PubMed:20724525). Inhibits lipopolysaccharide-induced apoptosis and
CC       hypertrophy in cardiomyocytes, via ubiquitination and subsequent
CC       proteasomal degradation of NFATC3 (PubMed:30980393). Collaborates with
CC       ATXN3 in the degradation of misfolded chaperone substrates: ATXN3
CC       restricting the length of ubiquitin chain attached to STUB1/CHIP
CC       substrates and preventing further chain extension (By similarity).
CC       Ubiquitinates NOS1 in concert with Hsp70 and Hsp40 (By similarity).
CC       Modulates the activity of several chaperone complexes, including Hsp70,
CC       Hsc70 and Hsp90 (By similarity). Ubiquitinates CHRNA3 targeting it for
CC       endoplasmic reticulum-associated degradation in cortical neurons, as
CC       part of the STUB1-VCP-UBXN2A complex (PubMed:26265139). Ubiquitinates
CC       and promotes ESR1 proteasomal degradation in response to age-related
CC       circulating estradiol (17-beta-estradiol/E2) decline, thereby promotes
CC       neuronal apoptosis in response to ischemic reperfusion injury
CC       (PubMed:21808025). Mediates transfer of non-canonical short ubiquitin
CC       chains to HSPA8 that have no effect on HSPA8 degradation (By
CC       similarity). Mediates polyubiquitination of DNA polymerase beta (POLB)
CC       at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-
CC       excision repair: catalyzes polyubiquitination by amplifying the
CC       HUWE1/ARF-BP1-dependent monoubiquitination and leading to POLB-
CC       degradation by the proteasome (By similarity). Mediates
CC       polyubiquitination of CYP3A4 (By similarity). Ubiquitinates EPHA2 and
CC       may regulate the receptor stability and activity through proteasomal
CC       degradation (By similarity). Acts as a co-chaperone for HSPA1A and
CC       HSPA1B chaperone proteins and promotes ubiquitin-mediated protein
CC       degradation (By similarity). Negatively regulates the suppressive
CC       function of regulatory T-cells (Treg) during inflammation by mediating
CC       the ubiquitination and degradation of FOXP3 in a HSPA1A/B-dependent
CC       manner (By similarity). Catalyzes monoubiquitination of SIRT6,
CC       preventing its degradation by the proteasome (By similarity). Likely
CC       mediates polyubiquitination and down-regulates plasma membrane
CC       expression of PD-L1/CD274, an immune inhibitory ligand critical for
CC       immune tolerance to self and antitumor immunity (By similarity).
CC       Negatively regulates TGF-beta signaling by modulating the basal level
CC       of SMAD3 via ubiquitin-mediated degradation (By similarity). Plays a
CC       role in the degradation of TP53 (By similarity). Mediates
CC       ubiquitination of RIPK3 leading to its subsequent proteasome-dependent
CC       degradation (By similarity). May regulate myosin assembly in striated
CC       muscles together with UBE4B and VCP/p97 by targeting myosin chaperone
CC       UNC45B for proteasomal degradation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9UNE7, ECO:0000250|UniProtKB:Q9WUD1,
CC       ECO:0000269|PubMed:19237536, ECO:0000269|PubMed:19483080,
CC       ECO:0000269|PubMed:20724525, ECO:0000269|PubMed:21808025,
CC       ECO:0000269|PubMed:26265139, ECO:0000269|PubMed:29934347,
CC       ECO:0000269|PubMed:30980393}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000250|UniProtKB:Q9WUD1};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000250|UniProtKB:Q9WUD1}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with BAG2, and with the
CC       E2 ubiquitin conjugating enzymes UBE2D1, UBE2D2 and UBE2D3. Detected in
CC       a ternary complex containing STUB1, HSPA1A and HSPBP1. Part of a
CC       complex composed of STUB1/CHIP, VCP/p97, CHRNA3, and UBXN2A that
CC       modulates the ubiquitination and endoplasmic reticulum-associated
CC       degradation (ERAD) of CHRNA3 (PubMed:26265139). Within the complex
CC       UBXN2A acts as a scaffold protein required for the interaction of
CC       CHRNA3 with VCP/p97, this interaction also inhibits CHRNA3
CC       ubiquitination by STUB1/CHIP and subsequently ERAD (PubMed:26265139).
CC       Interacts with MKKS. Interacts with DNAAF4 (By similarity). Interacts
CC       (via the U-box domain) with the UBE2V2-UBE2N heterodimer; the complex
CC       has a specific 'Lys-63'-linked polyubiquitination activity (By
CC       similarity). Interacts (when monoubiquitinated) with ATXN3 (By
CC       similarity). Interacts with UBE2W (By similarity). Interacts with
CC       DNAJB6 (By similarity). Interacts with FLCN and HSP90AA1. Interacts
CC       with HSP90. Interacts with UBE2N and UBE2V1. Interacts (via TPR
CC       repeats) with HSPA8 (via C-terminus) (By similarity). Interacts (via
CC       TPR repeats) with HSPA1A (via C-terminus) (PubMed:19237536). Interacts
CC       with the non-acetylated form of HSPA1A and HSPA1B. Interacts with SMAD3
CC       and HSP90AB1 (By similarity). Interacts with UBE4B (By similarity).
CC       Interacts with PRMT5 (By similarity). Interacts with MYOCD (via C-
CC       terminus) (PubMed:19237536). Interacts with FOXO1 (when phosphorylated
CC       on 'Ser-250') (By similarity). Interacts with MAPK7/ERK5; the
CC       interaction is enhanced in the presence of IGF1 or MAP2K5 and promotes
CC       STUB1/CHIP E3 ligase activity (By similarity). Interacts with and
CC       ubiquitinates ESR1; the interaction is promoted in the absence of
CC       estradiol (17-beta-estradiol/E2) (PubMed:21808025). Interacts with ESR2
CC       (PubMed:21808025). Interacts with and ubiquitinates NFATC3;
CC       HSPA1A/HSP70 is required as a co-chaperone (PubMed:30980393).
CC       {ECO:0000250|UniProtKB:Q9UNE7, ECO:0000250|UniProtKB:Q9WUD1,
CC       ECO:0000269|PubMed:19237536, ECO:0000269|PubMed:21808025,
CC       ECO:0000269|PubMed:26265139, ECO:0000269|PubMed:30980393}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19237536,
CC       ECO:0000269|PubMed:19483080, ECO:0000269|PubMed:30980393}. Nucleus
CC       {ECO:0000269|PubMed:19237536, ECO:0000269|PubMed:30980393}.
CC       Mitochondrion {ECO:0000269|PubMed:29934347}. Note=Translocates to the
CC       nucleus in response to inflammatory signals in regulatory T-cells
CC       (Treg) (By similarity). Localizes to mitochondria following oxygen and
CC       glucose deprivation-induced cellular stress (PubMed:29934347).
CC       {ECO:0000250|UniProtKB:Q9UNE7, ECO:0000269|PubMed:29934347}.
CC   -!- TISSUE SPECIFICITY: Expressed in the adventitia layer of the carotid
CC       artery (at protein level) (PubMed:19483080). Expressed in the CA1
CC       region of the hippocampus (at protein level) (PubMed:21808025).
CC       Expressed in the uterus (at protein level) (PubMed:21808025).
CC       {ECO:0000269|PubMed:19483080, ECO:0000269|PubMed:21808025}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in neurons at 18.5 dpc (at protein
CC       level). {ECO:0000269|PubMed:29934347}.
CC   -!- INDUCTION: Induced by oxygen and glucose deprivation in neuronal cells
CC       (PubMed:29934347). Induced in the neointimal layer of the carotid
CC       artery by blood flow cessation injury (PubMed:19483080).
CC       {ECO:0000269|PubMed:19483080, ECO:0000269|PubMed:29934347}.
CC   -!- DOMAIN: The U-box domain is required for the ubiquitin protein ligase
CC       activity. {ECO:0000250|UniProtKB:Q9WUD1}.
CC   -!- DOMAIN: The TPR domain is essential for ubiquitination mediated by
CC       UBE2D1. {ECO:0000250|UniProtKB:Q9UNE7}.
CC   -!- PTM: Auto-ubiquitinated; mediated by UBE2D1 and UBE2D2 and enhanced in
CC       the presence of MAP2K5 (By similarity). Monoubiquitinated at Lys-2
CC       following cell stress by UBE2W, promoting the interaction with ATXN3
CC       (By similarity). {ECO:0000250|UniProtKB:Q9UNE7,
CC       ECO:0000250|UniProtKB:Q9WUD1}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH473948; EDM03968.1; -; Genomic_DNA.
DR   RefSeq; NP_001020796.2; NM_001025625.2.
DR   SMR; A6HD62; -.
DR   IntAct; A6HD62; 2.
DR   PaxDb; 10116-ENSRNOP00000026921; -.
DR   Ensembl; ENSRNOT00000026921.7; ENSRNOP00000026921.4; ENSRNOG00000019798.7.
DR   GeneID; 287155; -.
DR   KEGG; rno:287155; -.
DR   AGR; RGD:1306167; -.
DR   CTD; 10273; -.
DR   RGD; 1306167; Stub1.
DR   eggNOG; KOG4642; Eukaryota.
DR   GeneTree; ENSGT00930000151045; -.
DR   HOGENOM; CLU_056455_1_0_1; -.
DR   OMA; WAGVEHD; -.
DR   OrthoDB; 313431at2759; -.
DR   TreeFam; TF313937; -.
DR   Reactome; R-RNO-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-RNO-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-RNO-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-RNO-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-RNO-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-RNO-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Proteomes; UP000234681; Chromosome 10.
DR   Bgee; ENSRNOG00000019798; Expressed in frontal cortex and 18 other tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0042405; C:nuclear inclusion body; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0101031; C:protein folding chaperone complex; ISO:RGD.
DR   GO; GO:0000151; C:ubiquitin ligase complex; ISO:RGD.
DR   GO; GO:0030018; C:Z disc; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; ISO:RGD.
DR   GO; GO:0031072; F:heat shock protein binding; ISO:RGD.
DR   GO; GO:0030544; F:Hsp70 protein binding; ISO:RGD.
DR   GO; GO:0051879; F:Hsp90 protein binding; ISO:RGD.
DR   GO; GO:0019900; F:kinase binding; ISO:RGD.
DR   GO; GO:0051787; F:misfolded protein binding; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0051087; F:protein-folding chaperone binding; ISO:RGD.
DR   GO; GO:0070412; F:R-SMAD binding; ISO:RGD.
DR   GO; GO:0046332; F:SMAD binding; ISO:RGD.
DR   GO; GO:0030911; F:TPR domain binding; ISO:RGD.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISO:RGD.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; ISO:RGD.
DR   GO; GO:0071218; P:cellular response to misfolded protein; ISO:RGD.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; ISO:RGD.
DR   GO; GO:0036503; P:ERAD pathway; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; IMP:UniProtKB.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISO:RGD.
DR   GO; GO:1904694; P:negative regulation of vascular associated smooth muscle contraction; IMP:UniProtKB.
DR   GO; GO:0090035; P:positive regulation of chaperone-mediated protein complex assembly; ISO:RGD.
DR   GO; GO:1904294; P:positive regulation of ERAD pathway; ISO:RGD.
DR   GO; GO:1901526; P:positive regulation of mitophagy; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISO:RGD.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; ISO:RGD.
DR   GO; GO:0045862; P:positive regulation of proteolysis; ISO:RGD.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISO:RGD.
DR   GO; GO:0051865; P:protein autoubiquitination; ISO:RGD.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; ISO:RGD.
DR   GO; GO:0006513; P:protein monoubiquitination; ISO:RGD.
DR   GO; GO:0000209; P:protein polyubiquitination; ISO:RGD.
DR   GO; GO:0006515; P:protein quality control for misfolded or incompletely synthesized proteins; ISO:RGD.
DR   GO; GO:0050821; P:protein stabilization; ISO:RGD.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0031943; P:regulation of glucocorticoid metabolic process; ISO:RGD.
DR   GO; GO:0031647; P:regulation of protein stability; ISO:RGD.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; ISO:RGD.
DR   CDD; cd16654; RING-Ubox_CHIP; 1.
DR   Gene3D; 6.10.140.2020; -; 1.
DR   Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR045202; CHIP_RING-Ubox.
DR   InterPro; IPR041312; CHIP_TPR_N.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   InterPro; IPR003613; Ubox_domain.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR46803; E3 UBIQUITIN-PROTEIN LIGASE CHIP; 1.
DR   PANTHER; PTHR46803:SF2; E3 UBIQUITIN-PROTEIN LIGASE CHIP; 1.
DR   Pfam; PF12895; ANAPC3; 1.
DR   Pfam; PF18391; CHIP_TPR_N; 1.
DR   Pfam; PF04564; U-box; 1.
DR   SMART; SM00028; TPR; 3.
DR   SMART; SM00504; Ubox; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   SUPFAM; SSF48452; TPR-like; 1.
DR   PROSITE; PS50005; TPR; 2.
DR   PROSITE; PS51698; U_BOX; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; DNA damage; DNA repair; Isopeptide bond; Mitochondrion; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; TPR repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN           1..304
FT                   /note="E3 ubiquitin-protein ligase CHIP"
FT                   /id="PRO_0000459701"
FT   REPEAT          27..60
FT                   /note="TPR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00339"
FT   REPEAT          61..94
FT                   /note="TPR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00339"
FT   REPEAT          96..128
FT                   /note="TPR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00339"
FT   DOMAIN          227..301
FT                   /note="U-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01034"
FT   REGION          1..30
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          102..201
FT                   /note="Required for interaction with MAPK7"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   REGION          143..197
FT                   /note="Required for interaction with and ubiquitination of
FT                   MYOCD"
FT                   /evidence="ECO:0000269|PubMed:19237536"
FT   REGION          144..304
FT                   /note="Required for ubiquitination of FOXO1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   REGION          144..198
FT                   /note="Required for interaction with FOXO1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   MOD_RES         20
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUD1"
FT   MOD_RES         24
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUD1"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUD1"
FT   MOD_RES         150
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   MOD_RES         274
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   CROSSLNK        2
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUD1"
FT   CROSSLNK        23
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   CROSSLNK        222
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
FT   CROSSLNK        256
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UNE7"
SQ   SEQUENCE   304 AA;  34886 MW;  E6BDCB223FAE1E6F CRC64;
     MKGKEEKEGG ARLGTGGGGS PDKSPSAQEL KEQGNRLFVG RKYPEAAACY GRAITRNPLV
     AVYYTNRALC YLKMQQPEQA LADCRRALEL DGQSVKAHFF LGQCQLEMES YDEAIANLQR
     AYSLAKEQRL NFGDDIPSAL RIAKKKRWNS IEERRIHQES ELHSYLTRLI AAERERELEE
     CQRNHEGDED DGHIRAQQAC IEAKHDKYMA DMNELFSQVD EKRKKRDIPD YLCGKISFEL
     MREPCITPSG ITYDRKDIEE HLQRVGHFDP VTRSPLTQEQ LIPNLAMKEV IDAFISENGW
     VEDY
//
